- Oral presentation
- Open Access
Three-dimensional microscopy of the human bronchial mucosa
© Riker et al; licensee BioMed Central Ltd. 2010
Published: 29 October 2010
Lung cancer is the leading cause of cancer related death, and despite recent efforts to reduce the mortality associated with the disease, patient prognosis remains poor with the current 5-year survival rate under 15%. Detection and diagnosis of lesions arising in the bronchial mucosa remains problematic and as a result they are typically well advanced upon discovery.
We are currently conducting a clinical study aimed at using optical frequency domain imaging (OFDI) to interrogate the bronchial mucosa of patients with the suspicion of lung cancer. During bronchoscopic evaluation, regions of interest suspicious for cancer or precursor lesions were identified and imaged, in addition to regions of normal appearing mucosa. Following OFDI imaging, mucosal biopsies were obtained for histopathologic analysis. Spiral cross-sectional OFDI images were obtained at a rate of 50 frames/sec using a 2.4 Fr catheter (frame size: 1536x1024; image resolution: 8μm x 23μm x 100μm).
The layered structure of the normal bronchial mucosa was clearly visualized in the OFDI images including the identification of the epithelium, lamina propria, smooth muscle, perichondrium and cartilage layers. In addition, features such as mucosal vasculature, glands, ducts and alveoli were observed. Various features associated with airway disease were also observed including the presence of fibrous debris, airway inflammation, and lymphatic and blood vasculature remodeling. Based on these preliminary results we anticipate that OFDI imaging of the pulmonary airways will enable the early detection of airway features associated with the development of cancer. When used as a screening tool in high-risk patients we hope that early detection of airway associated cancer with OFDI will result in a decrease in patient mortality.
Olympus Corporation, K99 CA134920
This article is published under license to BioMed Central Ltd.